BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?

Rajarshi, Keshav; Chatterjee, Aroni; Ray, Shashwati

doi:10.1016/j.medidd.2020.100049

Cited by 20 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The world population is facing a severe mass annihilation due to the rise of a global pandemic named Coronavirus Disease 2019 (COVID-19) (Boopathi et al., 2020 ; Chatterjee et al., 2020 ; Joshi et al., 2020 ; Kirchdoerfer et al., 2016 ). This pandemic is caused by a novel single-stranded RNA virus belonging to the β-coronavirus genera of the coronaviridae family (Elfiky & Azzam, 2020 ; Enmozhi et al., 2020 ; Khan et al., 2020 ; Rajarshi, Chatterjee & Ray 2020 ; Sarma et al., 2020 ; Sinha et al., 2020 ). As this virus shares significant phylogenetic similarity and structural familiarity (about 80% nucleotide identity and 89.10% nucleotide similarity) with the severe acute respiratory syndrome coronavirus (SARS-CoV), it has been named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and placed in the same lineage (Subgenus Sarbecovirus ) (2020; Boopathi et al., 2020 ; Das et al., 2020 ; Khan et al., 2020 ; Ou et al., 2020 ; Rajarshi, Chatterjee & Ray 2020 ).…”

Section: Introductionmentioning

confidence: 99%

“…This pandemic is caused by a novel single-stranded RNA virus belonging to the β-coronavirus genera of the coronaviridae family (Elfiky & Azzam, 2020 ; Enmozhi et al., 2020 ; Khan et al., 2020 ; Rajarshi, Chatterjee & Ray 2020 ; Sarma et al., 2020 ; Sinha et al., 2020 ). As this virus shares significant phylogenetic similarity and structural familiarity (about 80% nucleotide identity and 89.10% nucleotide similarity) with the severe acute respiratory syndrome coronavirus (SARS-CoV), it has been named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and placed in the same lineage (Subgenus Sarbecovirus ) (2020; Boopathi et al., 2020 ; Das et al., 2020 ; Khan et al., 2020 ; Ou et al., 2020 ; Rajarshi, Chatterjee & Ray 2020 ). To date, no effective regime of antivirals or vaccines is available for the use of the general public to combat the effect of COVID infections, which has put the population at a more vulnerable position (Aanouz et al., 2020 ; Elfiky, 2020 ; Elmezayen et al., 2020 ; Muralidharan et al., 2020 ; Pant et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: anin silicostudy for drug development

Pandey

Rane

Chatterjee

et al. 2020

Journal of Biomolecular Structure and Dynamics

Self Cite

208

162

View full text Add to dashboard Cite

Spike glycoprotein, a class I fusion protein harboring the surface of SARS-CoV-2 (SARS-CoV-2S), plays a seminal role in the viral infection starting from recognition of the host cell surface receptor, attachment to the fusion of the viral envelope with the host cells. Spike glycoprotein engages host Angiotensin-converting enzyme 2 (ACE2) receptors for entry into host cells, where the receptor recognition and attachment of spike glycoprotein to the ACE2 receptors is a prerequisite step and key determinant of the host cell and tissue tropism. Binding of spike glycoprotein to the ACE2 receptor triggers a cascade of structural transitions, including transition from a metastable pre-fusion to a postfusion form, thereby allowing membrane fusion and internalization of the virus. From ancient times people have relied on naturally occurring substances like phytochemicals to fight against diseases and infection. Among these phytochemicals, flavonoids and non-flavonoids have been the active sources of different anti-microbial agents. We performed molecular docking studies using 10 potential naturally occurring compounds (flavonoids/non-flavonoids) against the SARS-CoV-2 spike protein and compared their affinity with an FDA approved repurposed drug hydroxychloroquine (HCQ). Further, our molecular dynamics (MD) simulation and energy landscape studies with fisetin, quercetin, and kamferol revealed that these molecules bind with the hACE2-S complex with low binding free energy. The study provided an indication that these molecules might have the potential to perturb the binding of hACE2-S complex. In addition, ADME analysis also suggested that these molecules consist of drug-likeness property, which may be further explored as anti-SARS-CoV-2 agents.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: anin silicostudy for drug development

Pandey

Rane

Chatterjee

et al. 2020

Journal of Biomolecular Structure and Dynamics

Self Cite

208

162

View full text Add to dashboard Cite

show abstract

“…An approximately 30 kB long positive-sense single-stranded RNA constitutes the viral genome of the SARS-CoV-2. After the complete phylogenetic analysis of the RNA genome of the virus, it was revealed that 29,903 nucleotides were present in the viral genome, and it shared 89.1% similarity with the previously encountered SARS-CoV ( Rajarshi et al, 2020a , Rajarshi et al, 2020b ). The viral genome consisted of 5́ and 3́ UTRs (untranslated regions) at either end.…”

Section: Sars-cov-2: Structural Analysis and Essential Functional Molmentioning

confidence: 99%

Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19

Rajarshi

Khan²,

Singh

et al. 2021

Gene

Self Cite

View full text Add to dashboard Cite

“…It belongs to the β-coronavirus sub-family along with SARS-CoV and MERS-CoV [ 4 , 6 ]. The whole-genome sequence of SARS-CoV-2 consists of 29,903 nucleotides assigned with GenBank accession number MN908947 and the order of gene present was: replicase ORF1ab, spike (S), envelope (E), membrane (M) and nucleocapsid (N) in 5′ to 3′ direction of the viral genome [ 7 , 8 , 9 ]. WHO officially designated this new disease as coronavirus disease-2019, i.e., COVID-19.…”

Section: Introductionmentioning

confidence: 99%

“…These biomolecules have also been found to be effective during the previous epidemic due to SARS-CoV [ 17 ]. The phylogenetic analysis of SARS-CoV-2 with SARS-CoV has shown that they share 89.1% similarities among each other [ 7 , 8 , 9 ], the use of nucleic acid-based molecules against SARS-CoV-2 may emerge as a potential therapeutic strategy.…”

Section: Introductionmentioning

confidence: 99%

Nucleic acid-based therapy for coronavirus disease 2019

Piyush¹,

Rajarshi²,

Chatterjee³

et al. 2020

Heliyon

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), the pandemic that originated in China has already spread into more than 190 countries, resulting in huge loss of human life and many more are at the stake of losing it; if not intervened with the best therapeutics to contain the disease. For that aspect, various scientific groups are continuously involved in the development of an effective line of treatment to control the novel coronavirus from spreading rapidly. Worldwide scientists are evaluating various biomolecules and synthetic inhibitors against COVID-19; where the nucleic acid-based molecules may be considered as potential drug candidates. These molecules have been proved potentially effective against SARS-CoV, which shares high sequence similarity with SARS-CoV-2. Recent advancements in nucleic acid-based therapeutics are helpful in targeted drug delivery, safely and effectively. The use of nucleic acid-based molecules also known to regulate the level of gene expression inside the target cells. This review mainly focuses on various nucleic acid-based biologically active molecules and their therapeutic potentials in developing vaccines for SARS-CoV-2.

show abstract

BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope?

Cited by 20 publications

References 28 publications

Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: anin silicostudy for drug development

Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: anin silicostudy for drug development

Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19

Nucleic acid-based therapy for coronavirus disease 2019

Contact Info

Product

Resources

About